| Citation: |
XU Tian, YANG Lu, YUAN Fangqin, HE Xia, YIN Li. Relation Between EB Virus Infection and Curative Effect, Prognosis of Patients with Early-stage Extranodal Nasal-type NK/T-cell Lymphoma[J]. Cancer Research on Prevention and Treatment, 2021, 48(11): 999-1005. DOI: 10.3971/j.issn.1000-8578.2021.21.0216
|
To explore the correlation of pretreatment EBV DNA load, EBV EA-IgA and VCA-IgA antibodies levels with the clinical characteristics, curative effect and prognosis of the patients with early-stage extranodal nasal-type NK/T-cell lymphoma (ENKTCL).
We analyzed the clinical features and prognostic factors of 78 ENKTCL patients.
Positive rates of pretreatment EBV DNA, VCA-IgA and EA-IgA were 43.6%, 20.5% and 14.1%, respectively. EBV DNA was significantly associated with Ann Arbor stage, primary site, PTI and non-CR (all P < 0.05). VCA-IgA and EA-IgA were related to positive EBV DNA and non-CR (all P < 0.05). Multivariate analysis showed that age, EBV DNA and non-CR were independent prognostic factors for OS (all P < 0.05); age, EBV DNA, primary site and non-CR were independent prognostic factors for PFS (all P < 0.05).
The pretreatment positive EBV DNA is related to advanced Ann Arbor stage, PTI, primary extra-nasal subtypes of upper aerodigestive tract and poor response to treatment. The elevated levels of EA-IgA and VCA-IgA are related to positive EBV DNA and poor response to treatment. Pretreatment EBV DNA could be used for risk stratification and prognosis prediction of ENKTCL, while EA-IgA and VCA-IgA play limited role in guiding the prognosis of ENKTCL.
Competing interests: The authors declare that they have no competing interests.
| [1] |
Wang L, Li LR, Zhang L, et al. The landscape of new drugs in extranodal NK/T-cell lymphoma[J]. Cancer Treat Rev, 2020, 89: 102065. doi: 10.1016/j.ctrv.2020.102065
|
| [2] |
Tse E, Kwong YL. The diagnosis and management of NK/T-cell lymphomas[J]. J Hematol Oncol, 2017, 10(1): 85. doi: 10.1186/s13045-017-0452-9
|
| [3] |
Yamaguchi M, Suzuki R, Oguchi M. Advances in the treatment of extranodal NK/T-cell lymphoma, nasal type[J]. Blood, 2018, 131(23): 2528-2540. doi: 10.1182/blood-2017-12-791418
|
| [4] |
Huang Y, Rao H, Yan S, et al. Serum EBV EA-IgA and VCA-IgA antibodies can be used for risk group stratification and prognostic prediction in extranodal NK/T cell lymphoma: 24-year experience at a single institution[J]. Ann Hematol, 2017, 96(8): 1331-1342. doi: 10.1007/s00277-017-3013-y
|
| [5] |
Ha JY, Cho H, Sung H, et al. Superiority of Epstein-Barr Virus DNA in the Plasma Over Whole Blood for Prognostication of Extranodal NK/T Cell Lymphoma[J]. Front Oncol, 2020, 10: 594692. doi: 10.3389/fonc.2020.594692
|
| [6] |
Zhao Q, Fan S, Chang Y, et al. Clinical efficacy of cisplatin, dexamethasone, gemcitabine and pegaspargase (DDGP) in the initial treatment of advanced stage (stage Ⅲ-Ⅳ) extranodal NK/T-cell lymphoma, and its correlation with Epstein-Barr virus[J]. Cancer Manag Res, 2019, 11: 3555-3564. doi: 10.2147/CMAR.S191929
|
| [7] |
Kim SJ, Yoon DH, Jaccard A, et al. A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis[J]. Lancet Oncol, 2016, 17(3): 389-400. doi: 10.1016/S1470-2045(15)00533-1
|
| [8] |
Wang L, Wang H, Wang JH, et al. Post-treatment plasma EBV-DNA positivity predicts early relapse and poor prognosis for patients with extranodal NK/T cell lymphoma in the era of asparaginase[J]. Oncotarget, 2015, 6(30): 30317-30326. doi: 10.18632/oncotarget.4505
|
| [9] |
Kwong YL, Pang AWK, Leung AYH, et al. Quantification of circulating Epstein-Barr virus DNA in NK/T-cell lymphoma treated with the SMILE protocol: diagnostic and prognostic significance[J]. Leukemia, 2014, 28(4): 865-870. doi: 10.1038/leu.2013.212
|
| [10] |
Chen Y, Xin X, Cui Z, et al. Diagnostic Value of Serum Epstein-Barr Virus Capsid Antigen-IgA for Nasopharyngeal Carcinoma: a Meta-Analysis Based on 21 Studies[J]. Clin Lab, 2016, 62(6): 1155-1166. http://europepmc.org/abstract/med/27468579
|
| [11] |
Lin N, Ku W, Song Y, et al. Genome-Wide Analysis of Epstein-Barr Virus Isolated from Extranodal NK/T-Cell Lymphoma, Nasal Type[J]. Oncologist, 2019, 24(9): e905-e913. doi: 10.1634/theoncologist.2017-0588
|
| [12] |
Chen Y, Zheng X, Chen B, et al. The clinical significance of Epstein-Barr virus DNA in peripheral blood mononuclear cells in patients with non-Hodgkin lymphoma[J]. Leuk Lymphoma, 2017, 58(10): 2349-2355. doi: 10.1080/10428194.2017.1300894
|
| [13] |
Wu T, Yang Y, Zhu SY, et al. Risk-adapted survival benefit of IMRT in early-stage NKTCL: a multicenter study from the China Lymphoma Collaborative Group[J]. Blood Adv, 2018, 2(18): 2369-2377. doi: 10.1182/bloodadvances.2018021311
|
| [14] |
Wu RY, Liu K, Wang WH, et al. Patterns of Primary Tumor Invasion and Regional Lymph Node Spread Based on Magnetic Resonance Imaging in Early-Stage Nasal NK/T-cell Lymphoma: Implications for Clinical Target Volume Definition and Prognostic Significance[J]. Int J Radiat Oncol Biol Phys, 2017, 97(1): 50-59. doi: 10.1016/j.ijrobp.2016.09.013
|
| [15] |
Qi SN, Xu LM, Yuan ZY, et al. Effect of primary tumor invasion on treatment and survival in extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era: a multicenter study from the China Lymphoma Collaborative Group (CLCG)[J]. Leuk Lymphoma, 2019, 60(11): 2669-2678. doi: 10.1080/10428194.2019.1602265
|
| [16] |
Ito Y, Kimura H, Maeda Y, et al. Pretreatment EBV-DNA copy number is predictive of response and toxicities to SMILE chemotherapy for extranodal NK/T-cell lymphoma, nasal type[J]. Clin Cancer Res, 2012, 18(15): 4183-4190. doi: 10.1158/1078-0432.CCR-12-1064
|
| [17] |
Su YJ, Wang PN, Chang H, et al. Extranodal NK/T-cell lymphoma, nasal type: Clinical features, outcome, and prognostic factors in 101 cases[J]. Eur J Haematol, 2018, 101(3): 379-388. doi: 10.1111/ejh.13126
|
| [18] |
Liang JH, Wang L, Gale RP, et al. Efficacy of pegaspargase, etoposide, methotrexate and dexamethasone in newly diagnosed advanced-stage extra-nodal natural killer/T-cell lymphoma with the analysis of the prognosis of whole blood EBV-DNA[J]. Blood Cancer J, 2017, 7(9): e608. doi: 10.1038/bcj.2017.88
|
| [19] |
Wang XX, Li PF, Bai B, et al. Efficacy of significance of pre-, interim-, and post-treatment plasma Epstein-Barr virus DNA load in NK/T-cell lymphoma treated with P-GEMOX protocol[J]. Leuk Lymphoma, 2019, 60(8): 1917-1925. doi: 10.1080/10428194.2018.1563690
|
| [20] |
Winter JR, Jackson C, Lewis JE, et al. Predictors of Epstein-Barr virus serostatus and implications for vaccine policy: A systematic review of the literature[J]. J Global Health, 2020, 10(1): 010404. doi: 10.7189/jogh.10.010404
|
| [21] |
Rao D, Fu M, Chen Y, et al. A combination of two ELISA tests for nasopharyngeal carcinoma screening in endemic areas based on a case-control study[J]. PeerJ, 2020, 8: e10254. doi: 10.7717/peerj.10254
|
| [22] |
Yao JJ, Lin L, Jin YN, et al. Prognostic value of serum Epstein-Barr virus antibodies in patients with nasopharyngeal carcinoma and undetectable pretreatment Epstein-Barr virus DNA[J]. Cancer Sci, 2017, 108(8): 1640-1647. doi: 10.1111/cas.13296
|
| [23] |
Tan LP, Tan GW, Sivanesan VM, et al. Systematic comparison of plasma EBV DNA, anti-EBV antibodies and miRNA levels for early detection and prognosis of nasopharyngeal carcinoma[J]. Int J Cancer, 2020, 146(8): 2336-2347. doi: 10.1002/ijc.32656
|
Figures(1) / Tables(3)
This work is licensed under a Creative Commons Attribution 3.0 License.
Copyright © Editorial Department of Cancer Prevention Research 鄂公网安备 42011102005013号 鄂ICP备2022015867号
Supported by: Beijing Renhe Information Technology Co., Ltd. 
DownLoad: